Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
Gimv [BE0003699130/GIMB]   
[29/01/2021]

Gimv : Gimv announces share buyback in the context of a share purchase plan for its personnel

Antwerp, 29 January 2021, 7:30 am Gimv announces share buyback in the context of a share purchase plan for its personnel The Board of Directors of Gimv has decided, in application of Art. 7:215, §1, al. 3 of the Companies Code, to start a share buyback program of 40,000 shares in the framework of a share purchase plan for certain Gimv employees. Gimv... See more
 
Gimv [BE0003699130/GIMB]   
[19/01/2021]

Gimv : Gimv sells OTN Systems, a provider of telecommunication solutions for industrial markets, to listed Belden Inc.

Antwerp, 19 January 2021, 14:30 CET Gimv sells OTN Systems, a provider of telecommunication solutions for industrial markets, to listed Belden Inc. Gimv, coshareholders Manuardeo and management, today announce that they are selling OTN Systems to USbased Belden Inc., a global provider of telecommunication transmission and security solutions for corporate... See more
 
Gimv [BE0003699130/GIMB]   
[02/12/2020]

Gimv : Gimv sells Itho Daalderop-Climate for Life - Dutch market leader in integrated sustainable solutions for energy-neutral living in the Benelux - to Parcom

Antwerp BE / Schiedam NL, 2 December 2020, 7:30 CET EMBARGO Gimv sells Itho DaalderopClimate for Life Dutch market leader in integrated sustainable solutions for energyneutral living in the Benelux to Parcom Producer Itho Daalderop and service provider Klimaatgarant today announce an important step in their development. Gimv will sell its majority... See more
 
Gimv [BE0003699130/GIMB]   
[30/11/2020]

Gimv : Gimv is founding investor of Kinaset Therapeutics in a USD 40m Series A round – funds used to develop novel therapeutics for respiratory diseases

Antwerp BE / Medfield, MA US, 30 November 2020, 8:00 AM CET Gimv is founding investor of Kinaset Therapeutics in a USD 40m series A round – funds used to develop novel therapeutics for respiratory diseases Gimv invests in Kinaset Therapeutics alongside 5AM Ventures and Atlas Venture in a USD 40m Series A round to support the clinical development of... See more
 
Gimv [BE0003699130/GIMB]   
[19/11/2020]

Gimv : Gimv invests in SynOx Therapeutics which raises EUR 37 million to develop emactuzumab for treatment of tenosynovial giant cell tumors

Antwerp/Dublin, 19 November 2020, 7:30 AM CET Gimv invests in SynOx Therapeutics which raises EUR 37 million to develop emactuzumab for treatment of tenosynovial giant cell tumors Gimv is investing in newly formed SynOx Therapeutics through a Series A round of EUR 37 million along with HealthCap, Medicxi and Forbion. SynOx will continue the development of... See more